- Home
- MEIP vs OP Comparison
MEIP vs OP Comparison
Compare MEIP & OP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- OP
- Stock Information
- Founded
- MEIP 2000
- OP 2021
- Country
- MEIP United States
- OP Greece
- Employees
- MEIP N/A
- OP N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- OP
- Sector
- MEIP Health Care
- OP
- Exchange
- MEIP Nasdaq
- OP Nasdaq
- Market Cap
- MEIP 13.3M
- OP 14.3M
- IPO Year
- MEIP 2003
- OP N/A
- Fundamental
- Price
- MEIP $6.60
- OP $0.30
- Analyst Decision
- MEIP Hold
- OP
- Analyst Count
- MEIP 1
- OP 0
- Target Price
- MEIP N/A
- OP N/A
- AVG Volume (30 Days)
- MEIP 2.8M
- OP 10.3M
- Earning Date
- MEIP 09-18-2025
- OP 08-06-2025
- Dividend Yield
- MEIP N/A
- OP N/A
- EPS Growth
- MEIP N/A
- OP N/A
- EPS
- MEIP N/A
- OP N/A
- Revenue
- MEIP N/A
- OP $25,702,000.00
- Revenue This Year
- MEIP N/A
- OP N/A
- Revenue Next Year
- MEIP N/A
- OP N/A
- P/E Ratio
- MEIP N/A
- OP N/A
- Revenue Growth
- MEIP 33.76
- OP 35.58
- 52 Week Low
- MEIP $1.46
- OP $0.30
- 52 Week High
- MEIP $9.00
- OP $3.17
- Technical
- Relative Strength Index (RSI)
- MEIP 81.52
- OP 34.84
- Support Level
- MEIP $5.75
- OP $1.49
- Resistance Level
- MEIP $9.00
- OP $2.50
- Average True Range (ATR)
- MEIP 0.85
- OP 0.28
- MACD
- MEIP 0.39
- OP -0.17
- Stochastic Oscillator
- MEIP 62.50
- OP 0.45
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.